Correction to: Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals.
Morrell L. et al, (2019), BMC health services research, 19, 198 - 198
Immunotherapy-related hepatitis: Real-world experience from a tertiary centre
Cheung V. et al, (2019), Frontline Gastroenterology
A phase I study to assess the safety and tolerability of intravesical pembrolizumab in recurrent non-muscle invasive bladder cancer (NMIBC).
Woodcock VK. et al, (2019), JOURNAL OF CLINICAL ONCOLOGY, 37
Real-world data: the incidence, diagnosis, and management outcomes of patients with immunotherapy-related colitis in two tertiary centres
Cheung V. et al, (2019), JOURNAL OF CROHNS & COLITIS, 13, S137 - S138
BRN2 suppresses apoptosis, reprograms DNA damage repair and is associated with a high somatic mutation burden in melanoma
GODING C. et al, (2019), Genes and Development
Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.
Juric D. et al, (2019), JAMA oncology, 5, e184475 - e184475
Age-Related Changes in Tumoral Angiogenesis Drive Melanoma Metastasis and Response to Targeted Therapy
Ecker B. et al, (2019), ANNALS OF SURGICAL ONCOLOGY, 26, S38 - S39
Focused Ultrasound Hyperthermia for Targeted Drug Release from Thermosensitive Liposomes: Results from a Phase I Trial.
Gray MD. et al, (2019), Radiology, 181445 - 181445
Planning and Delivery of Ultrasound- Mediated Hyperthermia for Targeted Drug Release from Thermosensitive Liposomes: Results from a Phase I Trial
MIDDLETON MR. et al, (2019), Radiology
Routinely staging gastric cancer with 18F-FDG PET-CT detects additional metastases and predicts early recurrence and death after surgery.
Findlay JM. et al, (2019), European radiology
The Circulating Transcriptome as a Source of Biomarkers for Melanoma.
Solé C. et al, (2019), Cancers (Basel), 11
A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer.
Eyre TA. et al, (2019), Cancer, 125, 99 - 108
First-in-human Phase 1 study of f the bromondomain and extra-terminal motif inhibitor BAY 1238097: Emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity
Postel-Vinay S. et al, (2018), European Journal of Cancer
Alpelisib (BYL719) Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type ER+ Advanced Breast Cancer
Juric D. et al, (2018), JAMA Oncology
Long-term radiological and histological outcomes following selective internal radiation therapy to liver metastases from breast cancer.
Lyon PC. et al, (2018), Radiol Case Rep, 13, 1259 - 1266
Challenges in assessing response of oesophageal cancer to neoadjuvant therapy, and the potential of composite PET-CT and multimodal metrics
(2018), Journal of Thoracic Disease
Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF Melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial.
Urbonas V. et al, (2018), Annals of oncology : official journal of the European Society for Medical Oncology
Phase II trial Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF Melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial
MIDDLETON MR. et al, (2018), Annals of Oncology
Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Updated results from a phase 3 trial (CheckMate 238)
Weber JS. et al, (2018), BRITISH JOURNAL OF CANCER, 119, 41 - 42